ArticleScientific reports2016
Proteomic profiling reveals that collismycin A is an iron chelator.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Sulfur-Containing Microbial Natural Products and Their Role in Communal Interactions.Journal of natural products · 2025Review
- Inhibitory effect of copper chelators on the budding inAntimicrobial agents and chemotherapy · 2025Article
- Complete Genome Sequence, Biological Activities, and Metabolomic Profiles of Mangrove-Derived Streptomyces sp. SM1P.Current microbiology · 2025Article
- Unraveling the genomic diversity of the Pseudomonas putida group: exploring taxonomy, core pangenome, and antibiotic resistance mechanisms.FEMS microbiology reviews · 2024Review
- Characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole.Microbiology spectrum · 2024Article
- Natural transaminase fusions for biocatalysis.RSC advances · 2024Article
- Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling.Oncology research · 2023Article
- Laccase-mediated synthesis of bioactive natural products and their analogues.RSC chemical biology · 2022Review
- Investigating Alkylated Prodigiosenes and Their Cu(II)-Dependent Biological Activity: Interactions with DNA, Antimicrobial and Photoinduced Anticancer Activity.ChemMedChem · 2022Article
- Proteomics-based target identification of natural products affecting cancer metabolism.The Journal of antibiotics · 2021Review
- Target identification of anticancer natural products using a chemical proteomics approach.RSC advances · 2021Review
- Biological activities of polypyridyl-type ligands: implications for bioinorganic chemistry and light-activated metal complexes.Current opinion in chemical biology · 2021Review
- Morphological Profiling Identifies a Common Mode of Action for Small Molecules with Different Targets.Chembiochem : a European journal of chemical biology · 2020Article
- Anti-MRSA Activity of Actinomycin XFrontiers in microbiology · 2020Article
- Maipomycin A, a Novel Natural Compound With Promising Anti-biofilm Activity Against Gram-Negative Pathogenic Bacteria.Frontiers in microbiology · 2020Article
- Resistance to Bipyridyls Mediated by the TtgABC Efflux System inFrontiers in microbiology · 2020Article
- Article
- Collismycin C from the Micronesian Marine Bacterium Streptomyces sp. MC025 Inhibits Staphylococcus aureus Biofilm Formation.Marine drugs · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collismycin A (CMA), a microbial product, has anti-proliferative activity against cancer cells, but the mechanism of its action remains unknown. Here, we report the identification of the molecular target of CMA by ChemProteoBase, a proteome-based approach for drug target identification. ChemProteoBase profiling showed that CMA is closely clustered with di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone, an iron chelator. CMA bound to both Fe(II) and Fe(III) ions and formed a 2:1 chelator-iron complex with a redox-inactive center. CMA-induced cell growth inhibition was completely canceled by Fe(II) and Fe(III) ions, but not by other metal ions such as Zn(II) or Cu(II). Proteomic and transcriptomic analyses showed that CMA affects the glycolytic pathway due to the accumulation of HIF-1α. These results suggest that CMA acts as a specific iron chelator, leading to the inhibition of cancer cell growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.